Skip to content
thestock.space

On 6 Nov 2026, Ajanta Pharmaceuticals was priced at ₹3,307.70, or 32.7× trailing earnings, against an industry P/E of 28.7×, and the shares are 13% below their 52-week high. Its ROCE of 29% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 13% and 22% a year over 3 years. It has almost no debt, and its dividend yield is 1.9%. It is a mid-cap company with a market cap of ₹41,333 Cr, ranked 17th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 26% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹3,282.10
Day high
₹3,339.50
Day low
₹3,252.10
Prev. close
₹3,282.10
Volume
1.4 L

Health check

3 good · 3 fair
  • ReturnsIn line

    +25.7% over a year, better than 4 of 7 peers.

  • Price tagIn line

    P/E 32.7 vs industry 28.7.

  • GrowthStrong

    Sales +13.4%, profit +21.5% a year over 3 years.

  • ProfitabilityStrong

    ROCE 29.4% vs peer median 17.9%.

  • Balance sheetFair

    Practically debt-free, Piotroski 4 of 9.

  • Red flagsNone found

    No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Mid cap

₹41,333 Cr, #17 of 154 in its industry by size.

Defensive

Beta 0.23 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Sep 2026: sales ₹6,217 Cr · profit ₹1,263 Cr
Market cap
₹41,333 Cr
Mid cap
P/E
32.7
Industry 28.7
Price to book
8.51
Peers 4.99
Dividend yield
1.93%
ROE
27.5%
Peers 14.7%
ROCE
29.4%
Peers 17.9%
Debt to equity
0.03
Debt ₹154 Cr
EPS (TTM)
₹101.01
Face value ₹2
OPM (TTM)
29.7%
Net margin 20.3%
Sales growth
+32.5%
Latest quarter vs a year ago
Profit growth
+49.2%
Latest quarter vs a year ago
Price to sales
6.65
EV/EBITDA 23.5

Strengths and risks

Strengths

  • Return on equity of 27.5%.
  • Return on capital employed of 29.4%.
  • Practically debt-free.
  • Quarterly profit up 49.2% on a year ago.
  • Quarterly sales up 32.5% on a year ago.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Ajanta Pharmaceuticals

Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas…

Headquarters
Mumbai
Employees
10,421
Sector
Healthcare
ISIN
INE031B01049
Website
ajantapharma.com

Price range

52 weeks

₹2,445.80₹3,796.00

Today

₹3,252.10₹3,339.50
Avg volume (3M)
1.1 L
1-year return
plus 25.7%
From 52-week high
minus 12.9%

Analyst consensus

13 analysts
BuyMean target ₹3,865.77 plus 16.9%

Target range, with today’s price

Low ₹3,109.00High ₹4,330.00

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
AJANTPHARMAjanta Pharmaceuticals3,307.70plus 0.78%41,33332.78.5129.4%27.5%29.7%13.4%21.5%1.93%plus 25.7%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26Sep 26
1,303–1,3751,4221,6261,794
925–9681,0271,1311,247
378285407395494548
29.0%–29.6%27.8%30.4%30.5%
0–00037.4
5.3–5.12.43.22.2
41.3–43.545.444.547.6
331–359347447535
22.9%–23.7%23.2%25.2%27.5%
255–274267334388
20.43–21.9121.3426.7231.03

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+13.4%
Profit CAGR 3Y
+21.5%
EPS CAGR 3Y
+22.6%
ROE
27.5%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
3,7084,1624,5885,407
–+12.2%+10.2%+17.9%
2,8972,9813,3153,908
8111,1811,2731,500
21.9%28.4%27.7%27.7%
80.747.279.5162
5.87.220.716.1
131135144173
−9.428.31.9−94.7
7451,1141,1891,378
21.1%26.7%22.6%23.3%
5888169201,056
–+38.8%+12.8%+14.7%
45.8964.7773.5384.51

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
25.325.325.125.1
3,3633,5423,7654,502
35.635.347.4260
1,2551,0361,1771,368
4,6794,6385,0156,155
1,6981,7291,9002,121
209264185295
2922.728.429.8
840460614663
1,9022,1632,2873,046
4,6794,6385,0156,155

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
7927851,157529
−56065.4−377−429
−108−1,051−733−168
124−20147.3−67.7
−174−152−318−365
618633839164
−89.7−642−349−350

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 24.2% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you